Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cunningham, Anthony L. | - |
dc.contributor.author | Heineman, Thomas C. | - |
dc.contributor.author | Lal, Himal | - |
dc.contributor.author | Godeaux, Olivier | - |
dc.contributor.author | Chlibek, Roman | - |
dc.contributor.author | Hwang, Shinn-Jang | - |
dc.contributor.author | McElhaney, Janet E. | - |
dc.contributor.author | Vesikari, Timo | - |
dc.contributor.author | Andrews, Charles | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Esen, Meral | - |
dc.contributor.author | Ikematsu, Hideyuki | - |
dc.contributor.author | Choma, Martina Kovac | - |
dc.contributor.author | Pauksens, Karlis | - |
dc.contributor.author | Ravault, Stephanie | - |
dc.contributor.author | Salaun, Bruno | - |
dc.contributor.author | Schwarz, Tino F. | - |
dc.contributor.author | Smetana, Jan | - |
dc.contributor.author | Vanden Abeele, Carline | - |
dc.contributor.author | Van den Steen, Peter | - |
dc.contributor.author | Vastiau, Ilse | - |
dc.contributor.author | Weckx, Lily Yin | - |
dc.contributor.author | Levin, Myron J. | - |
dc.date.accessioned | 2021-09-02T10:29:34Z | - |
dc.date.available | 2021-09-02T10:29:34Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-06-01 | - |
dc.identifier.issn | 0022-1899 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/74972 | - |
dc.description.abstract | Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01(B) Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: >= 50; ZOE-70: >= 70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing >= 2 of 4 activation markers assessed (CD4(2+)) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD4(2+) T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained >= 5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS INC | - |
dc.subject | SUBUNIT CANDIDATE VACCINE | - |
dc.subject | T-CELL | - |
dc.subject | PHASE-II | - |
dc.subject | VIRUS | - |
dc.subject | PROTECTION | - |
dc.subject | EFFICACY | - |
dc.subject | SAFETY | - |
dc.subject | AS01 | - |
dc.subject | IMMUNOGENICITY | - |
dc.subject | CORRELATE | - |
dc.title | Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Won Suk | - |
dc.identifier.doi | 10.1093/infdis/jiy095 | - |
dc.identifier.scopusid | 2-s2.0-85048621140 | - |
dc.identifier.wosid | 000434081100009 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INFECTIOUS DISEASES, v.217, no.11, pp.1750 - 1760 | - |
dc.relation.isPartOf | JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.title | JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.volume | 217 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1750 | - |
dc.citation.endPage | 1760 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.subject.keywordPlus | SUBUNIT CANDIDATE VACCINE | - |
dc.subject.keywordPlus | T-CELL | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | PROTECTION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | AS01 | - |
dc.subject.keywordPlus | IMMUNOGENICITY | - |
dc.subject.keywordPlus | CORRELATE | - |
dc.subject.keywordAuthor | varicella-zoster virus | - |
dc.subject.keywordAuthor | herpes zoster vaccine | - |
dc.subject.keywordAuthor | gE subunit vaccine | - |
dc.subject.keywordAuthor | adjuvant system | - |
dc.subject.keywordAuthor | immunogenicity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.